Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2 Positive Metastatic Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07368998
What this trial is testing

To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 80
Large-scale testing (Phase 3)UnknownNCT03423199
What this trial is testing

PAlbociclib Plus Tamoxifen for the Treatment of Hormone Receptor-positive, HER2-negative Advanced Breast Cancer Women - Asian studY

Who this might be right for
Breast Neoplasms
National Cancer Center, Japan 180
Early research (Phase 1)Study completedNCT03153163
What this trial is testing

Study of the Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Participants With Locally Advanced Inoperable or Metastatic HER2+ Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 11
Testing effectiveness (Phase 2)Study completedNCT00679211
What this trial is testing

Trastuzumab-Mcc-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Genentech, Inc. 110
Testing effectiveness (Phase 2)Study completedNCT02049957
What this trial is testing

Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Calithera Biosciences, Inc 118
Post-approval studies (Phase 4)Study completedNCT02248571
What this trial is testing

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

Who this might be right for
Breast Cancer RecurrentHER2/Neu-negative Carcinoma of BreastHormone Receptor Positive Malignant Neoplasm of Breast
iOMEDICO AG 85
Early research (Phase 1)Study completedNCT01420146
What this trial is testing

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients

Who this might be right for
Breast NeoplasmsSecondaryHER2 Positive Carcinoma of Breast
Jules Bordet Institute 20
Early research (Phase 1)Temporarily pausedNCT04120246
What this trial is testing

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8HER2 Positive Breast CarcinomaMetastatic Breast Carcinoma+1 more
Veana Therapeutics 24
Testing effectiveness (Phase 2)WithdrawnNCT00057993
What this trial is testing

Trastuzumab and Exemestane in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Breast Cancer
Northwestern University
Testing effectiveness (Phase 2)Ended earlyNCT00824733
What this trial is testing

Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Bhuvaneswari Ramaswamy 6
Not applicableUnknownNCT06299852
What this trial is testing

Stereotactic Radiation Therapy for HE2-positive Oligometastatic Breast Cancer

Who this might be right for
HER2-positive Metastatic Breast CancerOligometastatic Disease
N.N. Petrov National Medical Research Center of Oncology 58
Not applicableLooking for participantsNCT06210776
What this trial is testing

Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Who this might be right for
HER2-positive Breast CancerHER2-low Breast CancerBreast Cancer+1 more
Daiichi Sankyo 800
Testing effectiveness (Phase 2)Looking for participantsNCT05608252
What this trial is testing

VS-6766+Abema+Fulv in Met HR+/HER- BC

Who this might be right for
Breast CancerHormone Receptor-positive Breast CancerHormone Receptor Positive HER-2 Negative Breast Cancer
Adrienne G. Waks 63
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06475443
What this trial is testing

Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs

Who this might be right for
Metastatic Breast Cancer in the Brain
Henan Cancer Hospital 32
Not applicableStudy completedNCT05769751
What this trial is testing

Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Daiichi Sankyo 865
Testing effectiveness (Phase 2)Active Not RecruitingNCT05319873
What this trial is testing

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+17 more
Jonsson Comprehensive Cancer Center 18
Post-approval studies (Phase 4)Active Not RecruitingNCT05161195
What this trial is testing

Roll-over Study to Allow Continued Access to Ribociclib

Who this might be right for
Metastatic Breast Cancer
Novartis Pharmaceuticals 134
Early research (Phase 1)Looking for participantsNCT06625775
What this trial is testing

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Who this might be right for
Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) 392
Large-scale testing (Phase 3)Ended earlyNCT00440622
What this trial is testing

Study of Gemcitabine and Herceptin Versus Xeloda and Herceptin in HER-2 (+) Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer
Hellenic Oncology Research Group 90
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07019337
What this trial is testing

Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer

Who this might be right for
HER2-positive Breast CancerMetastatic Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 100
Next Page